Recent

% | $
Quotes you view appear here for quick access.

Stryker Corporation Message Board

petersinger68 11 posts  |  Last Activity: Feb 14, 2011 11:15 AM Member since: Feb 7, 2011
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • petersinger68 by petersinger68 Feb 14, 2011 11:15 AM Flag

    Click on the link to get the latest EasyMed press release:


    http://www.easymedmobile.com/corporate/news.html

  • petersinger68 by petersinger68 Feb 8, 2011 10:31 AM Flag

    Medifocus MFS.V looks to have some real potential as it looks to begin phase III trials.

    -Currently entering Phase III trial in a very large disease category
    -Phase III criteria no more stringent than phase 2, where criteria was significantly exceeded
    -38 U.S. and international patents with 18 pending
    -Midpoint data release allowed by FDA
    -As for the business model, the majority of revenue will be from Medifocus' disposable probes that offer 90% gross margins
    -Market Cap under $7 million at $0.25 per share
    BSD Medical recently got approval for a similar technology in a smaller disease category and now has a $140+ million market cap

  • petersinger68 by petersinger68 Feb 8, 2011 10:20 AM Flag

    -Currently entering Phase III trial in a very large disease category
    Take a look at Medifocus MFS.V It seems to have some real potential with it entering Phase III trials.


    -Phase III criteria no more stringent than phase 2, where criteria was significantly exceeded
    -38 U.S. and international patents with 18 pending
    -Midpoint data release allowed by FDA
    -As for the business model, the majority of revenue will be from Medifocus' disposable probes that offer 90% gross margins
    -Market Cap under $7 million at $0.25 per share
    BSD Medical recently got approval for a similar technology in a smaller disease category and now has a $140+ million market cap

  • petersinger68 by petersinger68 Feb 8, 2011 10:18 AM Flag

    Take a look at Medifocus MFS.V. It seems to have great potential


    -Currently entering Phase III trial in a very large disease category
    -Phase III criteria no more stringent than phase 2, where criteria was significantly exceeded
    -38 U.S. and international patents with 18 pending
    -Midpoint data release allowed by FDA
    -As for the business model, the majority of revenue will be from Medifocus' disposable probes that offer 90% gross margins
    -Market Cap under $7 million at $0.25 per share
    BSD Medical recently got approval for a similar technology in a smaller disease category and now has a $140+ million market cap

  • petersinger68 by petersinger68 Feb 8, 2011 9:54 AM Flag

    Check out Medifocus, MFS.V, it seems like it could make a big move soon with all the news coming out.


    -Currently entering Phase III trial in a very large disease category
    -Phase III criteria no more stringent than phase 2, where criteria was significantly exceeded
    -38 U.S. and international patents with 18 pending
    -Midpoint data release allowed by FDA
    -As for the business model, the majority of revenue will be from Medifocus' disposable probes that offer 90% gross margins
    -Market Cap under $7 million at $0.25 per share
    BSD Medical recently got approval for a similar technology in a smaller disease category and now has a $140+ million market cap

  • petersinger68 by petersinger68 Feb 7, 2011 2:04 PM Flag

    -Currently entering Phase III trial in a very large disease category
    -Phase III criteria no more stringent than phase 2, where criteria was significantly exceeded
    -38 U.S. and international patents with 18 pending
    -Midpoint data release allowed by FDA
    -As for the business model, the majority of revenue will be from Medifocus' disposable probes that offer 90% gross margins
    -Market Cap under $7 million at $0.25 per share
    BSD Medical recently got approval for a similar technology in a smaller disease category and now has a $140+ million market cap

  • petersinger68 by petersinger68 Feb 7, 2011 2:00 PM Flag

    Take a look at Medifocus. Great, experienced management that founded Celsion (CLSN).

    -Currently entering Phase III trial in a very large disease category
    -Phase III criteria no more stringent than phase 2, where criteria was significantly exceeded
    -38 U.S. and international patents with 18 pending
    -Midpoint data release allowed by FDA
    -As for the business model, the majority of revenue will be from Medifocus' disposable probes that offer 90% gross margins
    -Market Cap under $7 million at $0.25 per share
    BSD Medical recently got approval for a similar technology in a smaller disease category and now has a $140+ million market cap

  • What do you all think about Medifocus, a company started by the founders of Celsion?


    -Currently entering Phase III trial in a very large disease category
    -Phase III criteria no more stringent than phase 2, where criteria was significantly exceeded
    -38 U.S. and international patents with 18 pending
    -Midpoint data release allowed by FDA
    -As for the business model, the majority of revenue will be from Medifocus' disposable probes that offer 90% gross margins
    -Market Cap under $7 million at $0.25 per share
    BSD Medical recently got approval for a similar technology in a smaller disease category and now has a $140+ million market cap

  • petersinger68 by petersinger68 Feb 7, 2011 11:26 AM Flag

    http://198.180.34.16/update.aspx?id=a5571



    -Currently entering Phase III trial in a very large disease category
    -Phase III criteria no more stringent than phase 2, where criteria was significantly exceeded
    -38 U.S. and international patents with 18 pending
    -Midpoint data release allowed by FDA
    -As for the business model, the majority of revenue will be from Medifocus' disposible probes that offer 90% gross margins
    -Market Cap under $7 million at $0.25 per share
    BSD Medical recently got approval for a similar technology in a smaller disease category and now has a $140+ million market cap

  • petersinger68 by petersinger68 Feb 7, 2011 9:46 AM Flag

    Take a look at this great opportunity.


    -Currently entering Phase III trial in a very large disease category
    -Phase III criteria no more stringent than phase 2, where criteria was significantly exceeded
    -38 U.S. and international patents with 18 pending
    -Midpoint data release allowed by FDA
    -As for the business model, the majority of revenue will be from Medifocus' disposible probes that offer 90% gross margins
    -Market Cap under $7 million at $0.25 per share
    BSD Medical recently got approval for a similar technology in a smaller disease category and now has a $140+ million market cap

  • petersinger68 by petersinger68 Feb 7, 2011 9:43 AM Flag

    Great opportunity!

    -Currently entering Phase III trial in a very large disease category
    -Phase III criteria no more stringent than phase 2, where criteria was significantly exceeded
    -38 U.S. and international patents with 18 pending
    -Midpoint data release allowed by FDA
    -As for the business model, the majority of revenue will be from Medifocus' disposible probes that offer 90% gross margins
    -Market Cap under $7 million at $0.25 per share
    BSD Medical recently got approval for a similar technology in a smaller disease category and now has a $140+ million market cap

SYK
99.69-1.39(-1.38%)Aug 28 4:04 PMEDT